NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 20 Feb 2023 (#08)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43

2. Requirement of preliminary data

3. Time to assemble the research team

4. Time available to work on the grant, taking into consideration other responsibilities

5. Time for internal review

Important Notices

NOT-HS-23-008 Notice of Intent to Publish Funding Opportunity Announcement to Implement and Evaluate New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID. Through this funding, AHRQ intends to support existing multidisciplinary Long COVID clinics to develop and implement new or improved care delivery models, provide services to more people with Long COVID, expand services offered, strengthen care coordination, implement and share best practices for Long COVID management, support the primary care community with Long COVID education and management, evaluate project success, and disseminate findings. AHRQ anticipates publishing the RFA in April or May 2023 and making up to $9,000,000 in awards by September 30, 2023.

National Cancer Institute Global Oncology Research Leadership Training Award for research institutions based in LMICs
The National Cancer Institute intents to fund research institutions based in LMICs to develop and implement contextualized educational activities (courses and mentoring) to cultivate professional skills integral to fostering successful research careers in LMICs. NCI is currently soliciting Letters of Intent from eligible LMIC institutions/organizations. A small number of full proposals will be invited from submissions received in response to this Call. Grant amounts are expected to be up to $200,000 in total costs to support projects over a two-year period. Successful Letters of Intent will offer a clear vision to bolster professional competencies of investigators in LMICs so that they are well equipped to initiate and lead research in their local institutions. Submit the LOI from Monday, March 06 2023 and before Tuesday, May 30 2023. An information session will be held on March 17th at 9:00 – 10:30 am ET. Link to join zoom meeting HERE.

Notices of Special Interest (NOSI)

NOT-CA-23-032 Administrative Supplements to Initiate or Augment Outreach to and Inclusion of Sexual and Gender Minority (SGM) Populations. National Cancer Institute (NCI) issued this NOSI describes an opportunity for supplemental funding to current grantees for studies that include sexual and gender minority (SGM) populations in cancer control research to enhance or accelerate the understanding of cancer-related health behaviors, care delivery, or health outcomes specific to the SGM population. The goal of this initiative is to supplement existing awards to collect new data and/or analyze existing data through inclusion of and/or outreach to SGM individuals. Application Due Date: *Submissions must be received by April 21, 2023,* at 5:00 PM local time of applicant organization for FY 2023

funding. This NOSI expires on April 22, 2023. Administrative supplement applications are limited to currently funded R01, R37, P01, U01, UM1, UG1, UG3, UH3, U19 projects supported by NCI. Requests for no-cost extensions on the parent grant to accommodate a supplement will not be permitted. PDs/PIs must hold an active award supported through NCI with sufficient time (minimum 1 year) left to complete the study proposed after the supplement has been awarded within the existing project period.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **PA-20-185** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **PA-20-184** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **PA-20-183** Research Project Grant (Parent R01 Clinical Trial Required)
- **PA-20-200** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **PA-20-195** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **PA-20-194** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **PA-20-196** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-23-099** **Type: R01**

Application Due Date: May 07, 2023 through to January 07, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this FOA is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications proposing a clinical trial, only low risk clinical trials will be supported.

Budget: Application budgets are limited to no more than $499,999 in direct costs in any year and need to reflect the actual needs of the proposed project**.** The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink: PAR-23-106** **Type: R21**

Application Due Date: May 07, 2023 through to January 07, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) (https://www.oar.nih.gov/hiv-policy-and-research/research-priorities) in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications proposing a clinical trial, only low risk clinical trials will be supported.

Budget: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

3. Biosimilar User Fee Act (BsUFA) Research Grant (U01) Clinical Trials Optional

Letter of Intent: 30 days prior to the application due date **Hyperlink: RFA-FD-23-026** **Type:U01**

Application Due Date: April 26, 2023, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this FOA is to support research projects that enhance biosimilar and interchangeable product development and regulatory science.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for 1 additional year(s) contingent upon annual appropriations, availability of funding and satisfactory awardee performance. FDA/CDER intends to commit up to $5 million, for fiscal year 2023 in support of this grant program. It is anticipated that up to five (5) awards will be made, not to exceed $1 million in total costs (direct plus indirect), per award. Application budgets need to reflect the actual needs of the proposed project. and should not exceed the following in total costs (direct and indirect): YR 01: $1,000,000. YR 02: $1,000,000. The scope of the proposed project should determine the project period. The maximum project period is two (2) years.

4. HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink: RFA-NS-24-018** **Type: UG3/UH3**

Application Due Date: July 10, 2023 & July 10, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities including, but not limited to a combination of omics, Quantitative Sensory Testing (QST), actigraphy, Electroencephalography (EEG), digital measures, etc.as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition may also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis. Studies to be supported by this FOA may include those necessary for the identification and initial biological, analytical, and clinical validation of pain biomarkers or biomarker signatures, and must include human samples and data as the source for candidate biomarkers or signatures identification and development if possible. If not, biomarkers or signatures resulting from identification in animal models must be verified in human samples at the end of the UG3 phase or during the UH3 phase. This initiative aims to deliver therapeutic response prediction and/or monitoring candidate pain biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation appropriate for use in clinical trial design or decision-making in clinical practice.

Budget: Issuing IC and partner components intend to issue 2-3 awards in 2022, 5-6 awards in 2023 and 3-4 awards in 2024. Awards issued under this FOA are part of funds set aside to support the HEAL (Helping to End Addiction Long-term) initiative. Application budgets are limited to <$500,000 in direct costs per year for the UG3 phase and up to $1,500,000 in direct costs per year of the UH3 phase. Applicants may seek two years of UG3 funding. The UH3 phase cannot exceed three years, since the total period of the UG3/UH3 award cannot be more than 5 years. The actual duration of individual projects will depend on successful achievement of milestones and conditions as described in Milestones Section of the program overview.